NFA
RVNC

Nationwide Fund Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Nationwide Fund Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-29,130
Closed -$803K – 2226
2017
Q3 		$803K Sell
29,130
-600
-2% -$14.5K ﹤0.01% 1926
2017
Q2 		$785K Buy
29,730
+3,300
+12% +$73.6K ﹤0.01% 1925
2017
Q1 		$550K Sell
26,430
-3,547
-12% -$72.9K ﹤0.01% 2112
2016
Q4 		$621K Sell
29,977
-1,579
-5% -$26.4K ﹤0.01% 2054
2016
Q3 		$512K Sell
31,556
-2,000
-6% -$29K ﹤0.01% 2167
2016
Q2 		$456K Buy
33,556
+16,477
+96% +$291K ﹤0.01% 2203
2016
Q1 		$298K Buy
17,079
+201
+1% +$4.09K ﹤0.01% 2349
2015
Q4 		$577K Buy
16,878
+1,497
+10% +$51.9K ﹤0.01% 2037
2015
Q3 		$458K Hold
15,381
– – ﹤0.01% 2165
2015
Q2 		$492K Sell
15,381
-464
-3% -$11.9K ﹤0.01% 2257
2015
Q1 		$328K Sell
15,845
-2,714
-15% -$46.9K ﹤0.01% 2454
2014
Q4 		$314K Sell
18,559
-591
-3% -$10.3K ﹤0.01% 2436
2014
Q3 		$370K Buy
19,150
+1,120
+6% +$29.2K ﹤0.01% 2386
2014
Q2 		$613K Buy
18,030
+2,912
+19% +$91.3K ﹤0.01% 2148
2014
Q1 		$476K Buy
+15,118
New +$472K ﹤0.01% 2081

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nationwide Fund Advisors's RVNC Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2017, closing a stake of 29,130 shares — an estimated $803K sold.

Nationwide Fund Advisors first reported a position in RVNC in Q1 2014 and held it in 15 quarters. The position peaked at $803K in Q3 2017. 115 funds tracked by Wall St. Rank hold RVNC as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 29,130 Revance Therapeutics, Inc. shares in Q4 2017, an estimated $803K.
  • Nationwide Fund Advisors first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 15 quarters.
  • Nationwide Fund Advisors's Revance Therapeutics, Inc. position peaked at $803K in Q3 2017.
  • 115 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.